M&A Deal Summary |
|
|---|---|
| Date | 2023-02-23 |
| Target | Gossamer Bio - Clinical Stage Integrin Activator Program |
| Sector | Life Science |
| Buyer(s) | 149 Bio |
| Sellers(s) | Gossamer Bio |
| Deal Type | Divestiture |
SEARCH BY
149 Bio is a startup company developing breakthrough medicines that target integrin receptors to treat diseases with high unmet need. 149 Bio is based in Miami, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
| Employees | 144 |
| Revenue | 115M USD (2024) |
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Gossamer Bio was founded in 2015 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-09-25 |
Respira
Palo Alto, California, United States Respira is a pharmaceutical development company focused on commercializing its high-efficiency, dry powder inhaler (DPI) drug delivery technologies for the treatment of important diseases with unmet clinical needs. Respira was founded in 2010 and is based in Palo Alto, California. |
Buy | - |
